Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Pharmacol Res ; 158: 104879, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32413483

RESUMO

Advanced glycation end products (AGEs) are destructive molecules in the body that, at high levels, contribute to the progression of various chronic diseases. Numerous studies have suggested a modifying effect of vitamin D on AGEs and their receptors. This study sought to summarize the effects of vitamin D on AGEs and their receptors, including receptor for AGEs (RAGE) and soluble receptor for AGEs (sRAGE). The search method initially identified 484 articles; 331 remained after duplicate removal. Thirty-five articles were screened and identified as relevant to the study topic. After critical analysis, 27 articles were included in the final analysis. Vitamin D treatment may possibly be beneficial to reduce AGE levels and to augment sRAGE levels, particularly in vitamin D-deficient situations. Treatment with this vitamin may be effective in reducing RAGE expression in some disease conditions, but might be even harmful under normal conditions. The inhibitory or stimulatory effects of vitamin D on AGE receptors are mediated by various signaling pathways, MAPK/NF-κB, ADAM10/MMP9 and AT1R. In populations with chronic diseases and concomitant hypovitaminosis D, vitamin D supplementation can be used as a strategy to ameliorate AGE-mediated complications by modifying the AGE-RAGE and sRAGE systems.


Assuntos
Produtos Finais de Glicação Avançada/metabolismo , Receptor para Produtos Finais de Glicação Avançada/metabolismo , Deficiência de Vitamina D/tratamento farmacológico , Deficiência de Vitamina D/metabolismo , Vitamina D/administração & dosagem , Vitamina D/metabolismo , Animais , Produtos Finais de Glicação Avançada/antagonistas & inibidores , Humanos , Mediadores da Inflamação/antagonistas & inibidores , Mediadores da Inflamação/metabolismo , Receptor para Produtos Finais de Glicação Avançada/agonistas
2.
Nutrients ; 8(8)2016 Jul 25.
Artigo em Inglês | MEDLINE | ID: mdl-27463726

RESUMO

Diabetic retinopathy (DR), the most ordinary and specific microvascular complication of diabetes, is a disease of the retina. Zerumbone (ZER) is a monocyclic sesquiterpene compound, and based on reports, it is the predominant bioactive compound from the rhizomes of Zingiber zerumbet. The aim of the current study is to evaluate the protective effect of zerumbone against DR in streptozotocin (STZ)-induced diabetic rats. STZ-diabetic rats were treated with ZER (40 mg/kg) once a day orally for 8 weeks. ZER administration significantly (p < 0.05) lowered the levels of plasma glucose (32.5% ± 5.7% lower) and glycosylated hemoglobin (29.2% ± 3.4% lower) in STZ-diabetic rats. Retinal histopathological observations indicated that disarrangement and reduction in thickness of retinal layers were reversed in ZER-treated diabetic rats. ZER downregulated both the elevated levels of advanced glycosylated end products (AGEs) and the higher levels of the receptors for AGEs (RAGE) in retinas of diabetic rats. What's more, ZER significantly (p < 0.05) ameliorated diabetes-induced upregulation of tumor necrosis factor-α, interleukin (IL)-1 and IL-6. ZER also attenuated overexpression of vascular endothelial growth factor and intercellular adhesion molecule-1, and suppressed activation of nuclear factor (NF)-κB and apoptosis in the retinas of STZ-diabetic rats. Our results suggest ZER possesses retinal protective effects, which might be associated with the blockade of the AGEs/RAGE/NF-κB pathway and its anti-inflammatory activity.


Assuntos
Diabetes Mellitus Experimental/dietoterapia , Retinopatia Diabética/prevenção & controle , Suplementos Nutricionais , Hipoglicemiantes/uso terapêutico , Rizoma/química , Sesquiterpenos/uso terapêutico , Zingiberaceae/química , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Biomarcadores/sangue , Biomarcadores/metabolismo , Citocinas/antagonistas & inibidores , Citocinas/sangue , Diabetes Mellitus Experimental/complicações , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patologia , Retinopatia Diabética/imunologia , Hemoglobinas Glicadas/análise , Produtos Finais de Glicação Avançada/antagonistas & inibidores , Produtos Finais de Glicação Avançada/sangue , Hiperglicemia/prevenção & controle , Molécula 1 de Adesão Intercelular/química , Molécula 1 de Adesão Intercelular/metabolismo , Masculino , NF-kappa B/antagonistas & inibidores , NF-kappa B/metabolismo , Distribuição Aleatória , Ratos Wistar , Receptor para Produtos Finais de Glicação Avançada/agonistas , Receptor para Produtos Finais de Glicação Avançada/metabolismo , Retina/imunologia , Retina/metabolismo , Retina/patologia , Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fatores de Crescimento do Endotélio Vascular/metabolismo
3.
Am J Physiol Endocrinol Metab ; 309(10): E829-39, 2015 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-26394662

RESUMO

Nε-(carboxymethyl) lysine-conjugated bovine serum albumin (CML-BSA) is a major component of advanced glycation end products (AGEs). We hypothesised that AGEs reduce insulin secretion from pancreatic ß-cells by damaging mitochondrial functions and inducing mitophagy. Mitochondrial morphology and the occurrence of autophagy were examined in pancreatic islets of diabetic db/db mice and in the cultured CML-BSA-treated insulinoma cell line RIN-m5F. In addition, the effects of α-lipoic acid (ALA) on mitochondria in AGE-damaged tissues were evaluated. The diabetic db/db mouse exhibited an increase in the number of autophagosomes in damaged mitochondria and receptor for AGEs (RAGE). Treatment of db/db mice with ALA for 12 wk increased the number of mitochondria with well-organized cristae and fewer autophagosomes. Treatment of RIN-m5F cells with CML-BSA increased the level of RAGE protein and autophagosome formation, caused mitochondrial dysfunction, and decreased insulin secretion. CML-BSA also reduced mitochondrial membrane potential and ATP production, increased ROS and lipid peroxide production, and caused mitochondrial DNA deletions. Elevated fission protein dynamin-related protein 1 (Drp1) level and mitochondrial fragmentation demonstrated the unbalance of mitochondrial fusion and fission in CML-BSA-treated cells. Additionally, increased levels of Parkin and PTEN-induced putative kinase 1 protein suggest that fragmented mitochondria were associated with increased mitophagic activity, and ALA attenuated the CML-BSA-induced mitophage formation. Our study demonstrated that CML-BSA induced mitochondrial dysfunction and mitophagy in pancreatic ß-cells. The findings from this study suggest that increased concentration of AGEs may damage ß-cells and reduce insulin secretion.


Assuntos
Diabetes Mellitus/metabolismo , Produtos Finais de Glicação Avançada/metabolismo , Células Secretoras de Insulina/metabolismo , Insulina/metabolismo , Lisina/análogos & derivados , Dinâmica Mitocondrial , Mitofagia , Animais , Antioxidantes/metabolismo , Antioxidantes/uso terapêutico , Biomarcadores/metabolismo , Linhagem Celular Tumoral , Diabetes Mellitus/dietoterapia , Diabetes Mellitus/patologia , Suplementos Nutricionais , Regulação para Baixo/efeitos dos fármacos , Produtos Finais de Glicação Avançada/antagonistas & inibidores , Produtos Finais de Glicação Avançada/farmacologia , Secreção de Insulina , Células Secretoras de Insulina/efeitos dos fármacos , Células Secretoras de Insulina/ultraestrutura , Lisina/antagonistas & inibidores , Lisina/metabolismo , Masculino , Camundongos Endogâmicos C57BL , Camundongos Mutantes , Dinâmica Mitocondrial/efeitos dos fármacos , Mitofagia/efeitos dos fármacos , Oxidantes/antagonistas & inibidores , Oxidantes/farmacologia , Fagossomos/efeitos dos fármacos , Fagossomos/metabolismo , Fagossomos/ultraestrutura , Ratos , Receptor para Produtos Finais de Glicação Avançada/agonistas , Receptor para Produtos Finais de Glicação Avançada/metabolismo , Soroalbumina Bovina/antagonistas & inibidores , Soroalbumina Bovina/farmacologia , Ácido Tióctico/metabolismo , Ácido Tióctico/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA